



ASX Appendix 3Y – Change of Director’s Interest Notice

VALENCIA, Calif., January 2, 2024 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), refers to the ASX release dated 2 January 2024 (United States) / 3 January 2024 (Australia) confirming the vesting of various restricted stock units for Director, James Corbett in connection with the fulfilment of the relevant vesting milestones.

Pursuant to the above, please find attached an ASX Appendix 3Y recording a change in Mr James Corbett’s interests in the Company.

Please note that the disposal of shares by Mr Corbett by way of an on market sale (as reflected in the attached ASX Appendix 3Y) was executed solely for the purposes of satisfying Mr. Corbett’s income tax liability.

About AVITA Medical, Inc.

AVITA Medical® is a regenerative medicine company leading the development and commercialization of devices and autologous cellular therapies for skin restoration. The RECELL® System technology platform, approved by the Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects and for repigmentation of stable depigmented vitiligo lesions, harnesses the regenerative properties of a patient’s own skin to create Spray-On Skin™ cells. Delivered at the point-of-care, RECELL enables improved clinical outcomes. RECELL is the catalyst of a new treatment paradigm and AVITA Medical is leveraging its proven and differentiated capabilities to develop first-in-class cellular therapies for multiple indications.

In international markets, our products are approved under the RECELL System brand to promote skin healing in a wide range of applications including burns, full-thickness skin defects, and vitiligo. The RECELL System is TGA-registered in Australia, received CE-mark approval in Europe and has PMDA approval in Japan.

To learn more, visit www.avitamedical.com.

Investor & Media Contact:

Jessica Ekeberg

Phone +1-661-904-9269

investor@avitamedical.com

media@avitamedical.com

Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: AVITA Medical, Inc. ("Company")
ARBN: 641 288 155

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	James Corbett
Date of last notice	15 June 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	22 December 2023 (United States) / 23 December 2023 (Australia) & 26 December 2023 (United States) / 27 December 2023 (Australia)

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	<p>5,783 unquoted restricted stock units in the Company to acquire shares of common stock of the Company (which may be represented by CHES Depository Interests ("CDIs") ("RSUs"))</p> <p>7,242 of common stock of the Company (which may be represented by CDIs)</p> <p>7,475 unquoted options in the Company to acquire shares of common stock of the Company (which may be represented by CDIs) ("Options") expiring 23 Dec 2031 ex USD \$12.18</p> <p>226,296 Options expiring 29 Sep 2032 ex USD \$5.64</p> <p>100,000 Options expiring 7 June 2033 ex USD \$14.17</p>
Class	Common Stock
Number acquired	2,892 Common Stock (23 December 2023)
Number disposed	2,892 RSUs (23 December 2023) 1,445 Common Stock (27 December 2023)
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil consideration
No. of securities held after change	<p>2,891 RSUs</p> <p>8,689 of common stock of the Company (which may be represented by CDIs)</p> <p>7,475 Options expiring 23 Dec 2031 ex USD \$12.18</p> <p>226,296 Options expiring 29 Sep 2032 ex USD \$5.64</p> <p>100,000 Options expiring 7 June 2033 ex USD \$14.17</p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Common Stock upon conversion of Restricted Stock Units (23 December 2023) and sale of 1,445 Common Stock (27 December 2023).

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.